Human Insulin Market Trends and Overview

The market size of Human Insulin was valued at USD 18.93 billion in 2022. It is projected to reach USD 20.99 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 1.3% during the forecast period from 2023 to 2030.

Human Insulin, a vital component in the treatment of diabetes, has witnessed significant growth in recent years. With the rising prevalence of diabetes worldwide, the demand for human insulin is expected to continue its upward trajectory. The market's value is anticipated to reach USD 20.99 billion by 2030, reflecting a steady growth rate.

The forecasted Compound Annual Growth Rate (CAGR) of 1.3% indicates a gradual but consistent expansion of the human insulin market. This growth can be attributed to various factors, including advancements in medical technology, increasing awareness about diabetes management, and the development of innovative insulin delivery systems.

Furthermore, the market's growth is driven by the rising geriatric population, which is more susceptible to diabetes. Additionally, the sedentary lifestyle and unhealthy dietary habits prevalent in modern society contribute to the increasing incidence of diabetes, further fueling the demand for human insulin.

Geographically, North America currently dominates the human insulin market, accounting for a significant share. This can be attributed to the high prevalence of diabetes in the region, coupled with the presence of well-established healthcare infrastructure and favorable reimbursement policies. However, the Asia Pacific region is expected to witness substantial growth during the forecast period, owing to the increasing diabetic population and improving healthcare facilities.

In conclusion, the human insulin market is poised for steady growth in the coming years. Factors such as the rising prevalence of diabetes, technological advancements, and increasing awareness about diabetes management contribute to this growth. With a projected market value of USD 20.99 billion by 2030 and a CAGR of 1.3%, the human insulin market presents lucrative opportunities for industry players and investors alike.

Get Free Sample Report @


By Type:

  • Traditional human insulin
  • Analogue insulin

By Diabetes Type:

  • Type 1
  • Type 2

By Distribution Channel:

  • Hospital Pharmacy
  • Online pharmacy
  • Retails

Some of the major key players are as follows: Novo Nordisk, Companion Medical Inc., Valeritas Inc., Insulet Corporation, Cellenovo, Emperra Gmbh E-Health Technologies, F Hoffmann-La Roche, Ypsomed., Tandem Diabetes Care, Medtronic Inc players are listed in the final reports.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand — Head of Business Development & Strategy,

[email protected],

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND),